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patients recruited through an agency, Twitter and Asthma UK’s website. Participants 
had experienced a NCS and a SS < 3 years previously. Medication history and Asthma 
Control Test (ACT) scores were collected. Interviews were audio-recorded, and the-
matically analysed. Results: The sample was 69% Caucasian, with six males and 
seven females, and a mean age= 47. Most were working full time or retired, and had 
many years since asthma diagnosis (mean= 22 years). NCS were related to reliever 
(n= 7), preventer (n= 4) or both (n= 2) medications with the most common NCS from 
one brand to another (n= 4). Participants reported negative feelings, difficulty using 
the medication and ineffective symptom control. Most participants used the NCS 
medication < 6 months (range < 24 hours–2 years). The SS for most was a return to 
their original pre-NCS medication (n= 11). Although most found getting their SS 
straightforward, this required at least two HCP visits for half the sample, and took 
up to two months to obtain. Most expected symptoms to improve following the SS 
but nine participants still had sub-optimal ACT scores. Lasting impacts included 
damaged relationships with HCPs, strong views about NCS and concern about NCS 
reoccurrence. ConClusions: Failure to inform and involve patients in medication 
changes can have lasting impacts. It is important to note that NCS can incur costs 
associated with rejection of medicines and additional consultations, thus negating 
any attempt at cost saving.
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objeCtives: To evaluate the degree to which the officially pre-determined cost 
and average length of stay (ALoS) per selected KEN-DRG reflect actual resource 
use and to investigate other factors (e. g. size, type and location of hospital) corre-
lated with charges and ALoS. Methods: Data were from the Health Regions data 
base and included discharges, ALoS, and charges in NHS Hospitals for the selected 
KEN-DRGs. Predetermined ALoS and cost per KEN-DRG were derived from Gazette 
946/27/03/2012. Continuous variables did not follow normal distribution, so non 
parametric methods (Spearman’s correlation coefficient, Kruskal-Wallis test and 
Mann-Whitney test) were used. A two sided p-value ≤ 0.05 was considered statis-
tically significant. Results: Higher length of stay compared with the officially 
pre-determined was found for Chronic Obstructive Pulmonary Disease (COPD) 
with complications (10.8 vs 9 days), Bronchitis & Asthma with complications (5.8 
vs 4 days), Bronchitis & Asthma without complications (2.7 vs 2 days) and Breast 
Cancer with complications (7.9 vs 5 days). Consequently, officially pre-determined 
cost for Breast Cancer with complications (€ 965), Bronchitis & Asthma with com-
plications (€ 792) and COPD with complications (€ 1,446) represents less than 90% 
of total hospital charges (total actual average charge: € 1,186; € 929; € 1,634 respec-
tively). However, for the rest of the DRGs, under study, there were none or limited 
additional hospital charges. For all KEN-DRGs, size and population density was 
positively correlated with total charges (rs= 0.12, p= 0.018; median for Athens = 863 
& semi-urban= 752 p= 0.09 respectively). Moreover, for Bronchitis & Asthma with and 
without complications, population density was found to be positively correlated 
with ALoS (median for urban areas= 5.1 and semi-urban= 4.7; p= 0.09 and median 
for urban areas= 3 and semi-urban= 2.5; p= 0.03 respectively). ConClusions: The 
introduction of KEN-DRGs was a useful first step to modernize the hospital reim-
bursement system. However, further revisions are required in order for KEN-DRGs 
to become more useful.
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objeCtives: Asthma is under-diagnosed and under-treated in elderly, and utili-
zation of asthma medications in this population is not well characterized. This 
study describes utilization patterns of asthma medications in newly diagnosed 
≥ 50 patients. Methods: Medicare enrollees are followed for 12 months after first 
asthma diagnosis between Q1 2004- Q3 2012 (ICD-9-CM code: 493*). Treatment pat-
tern analysis was applied to initiators of asthma medications. Patients with > 1 
prescription of second-line therapy following exposure to first-line therapy are con-
sidered therapy switchers or augmenters. Patients with history of chronic obstruc-
tive pulmonary disease are excluded (ICD-9-CM codes: 490, 491*, 492*, 494*, 495* 
& 496). Results: Among 126,176 elderlies with asthma, 24,021 initiated asthma 
therapy within 12 months of asthma diagnosis (70% women, median age 70 years). 
319 (1.3%) continued therapy with one drug class (first-line therapy); 13,940 (58%) 
discontinued first-line therapy; 3,469 (14.4%) switched to another drug class (sec-
ond-line therapy); and 6,293 (26.2%) added second-line therapy (augmented). About 
34% of patients initiated therapy with inhaled short-acting beta-agonists (SABA); 
majority of them either discontinued SABA or added a controller medication. 19% 
of elderly patients started with oral corticosteroids after asthma diagnosis, 77% 
discontinued them and 12% switched to another asthma controller. Among con-
troller medications, inhaled corticosteroids (ICS) /long-acting beta-agonists (LABA) 
combination therapy, ICS monotherapy, and leukotriene antagonists respectively 
accounted for 19%, 12%, and 11% of treatment initiators. The majority of these anti-
are directly and indirectly linked with HRQoL of TB patients. Methods: A prospec-
tive cross-sectional study was conducted at a tertiary care hospital in a province 
of Pakistan, the Punjab. Data was collected by using WHOQOL-BREF question-
naire (Urdu version, pretested for reliability and validity) by means of face-to-face 
interviews and where possible by gender-based focus group sessions. In addition, 
facilitators also used few open-ended questions in order to get patients’ demo-
graphic and socioeconomic data. Participants were also asked to share their per-
sonal experiences of being diagnosed and treated with TB and what impact it had 
on their life style. All obtained data were analyzed using descriptive and inferen-
tial statistics. Results: The overall Cronbach’s alpha coefficient of the revalidated 
WHOQOL-BREF questionnaire was 0.785. The confirmatory factor analysis also pro-
vided an acceptable fit to a four-factor model in the studied sample. The scores for 
negative feelings, blue mood, depression, living place, personal relationships and 
sex life were significantly different in the psychological health and social relations 
domains. Age, gender and physical exercise were also significantly associated with 
the HRQoL of the patients. ConClusions: The WHOQOL-BREF was reliable and 
valid in the assessment of the HRQoL of TB patients in Pakistan. Despite the ability 
to cure TB, there was a significant impact on HRQoL of the TB patients. Till today, 
much attention is spent on curative and preventative mechanisms whereas the 
impact of TB on HRQoL is often neglected.
PRS79
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objeCtives: To assess published data on perennial allergic rhinitis/house dust 
mite allergic (PAR) patients and seasonal allergic rhinitis/grass pollen allergic (SAR) 
patients in order to establish the burden of allergic rhinitis (AR) and allergic asthma 
from both a quality of life (QoL) and cost perspective. Methods: A systematic liter-
ature review was conducted using Medline and Embase in eight pre-specified coun-
tries for the time period of January 2000 to January 2014. Search terms were related 
to QoL and/or cost. A total of 2963 abstracts and titles were identified. 50 abstracts 
met predefined criteria and provided data for calculations and collation. Results: 
Based on the RQLQ, the overall QoL of PAR patients was significantly worse than that 
of SAR patients (2.73 ± 0.12 cf. 2.04 ± 0.18, p≤ 0.001). In general, practical problems 
(mean: 3.80 ± SE: 0.08) and activities (mean: 3.70 ± SE: 0.11) were the most affected 
domains. Measured by the physical component score from the SF-36 questionnaire, 
the overall QoL of PAR patients was worse (p= 0.002) than that of SAR patients (49.06 
± 1.26 cf. 64.19 ± 7.89). For both PAR and SAR patients, domains measured by the 
SF-36 showed that vitality (mean: 59.95 ± SE: 3.24) was the most affected domain. 
Based on RQLQ, allergy immunotherapy improves eye symptoms, nasal symptoms, 
activities and practical problems the most in grass allergic patients. Direct compari-
son of total direct and indirect costs was complicated by differences in individual 
costs assessed among studies, however, the primary burden of costs is indirect 
and caused by high absenteeism and presenteeism. ConClusions: The QoL and 
economic burden of AR was substantial in the countries included in this review. 
However, limitations regarding the number of studies per country, heterogeneity 
between studies, and the lack of presented data have restricted the conclusions 
that could be drawn.
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objeCtives: To determine the Quality of Life (QoL) of bronchial asthma patients in 
a tertiary care teaching hospital at baseline and at follow up. Methods: The study 
was conducted for a period of 6 months among 100 bronchial asthma patients, with 
and without co-morbidities, admitted to the pulmonary and medicine wards in 
the university hospital after obtaining the ethical clearance. The quality of life was 
assessed using Asthma Quality Of life Questionnaire (AQLQ). Patients were followed 
up after 4weeks from the date of discharge. Statistical analysis was performed using 
SPSS version 20. Results: The mean age of the study population was 53.30±14.59 
having 61% of the patients as females. Data was analyzed by Wilcoxon signed rank 
test. The total score of Qol at follow up (5.94 ±0.76) showed an improvement with 
a P value < 0.0001 (wilcoxon signed rank t test) when compared with baseline (3.92 
± 1.04). A significant improvement in symptoms was seen at follow up (6.05 ± 0.82) 
from baseline (3.93 ± 1.14). The activity limitation improved with a P value < 0.0001 
(Wilcoxon signed rank t test) from baseline (4.00 ± 1.08) to follow up (5.92 ± 0.83). At 
follow up (5.97 ± 0.82) the emotional function showed an enhancement on compar-
ing with baseline (3.92 ± 1.14). The environmental stimuli showed no significant 
changes at baseline (3.66 ± 1.29) and follow up (3.84 ± 1.34). ConClusions: The 
results of the study suggests that clinical pharmacists have a major role in improv-
ing patient knowledge and thereby significantly improve the quality of life of the 
patient.
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objeCtives: Patient satisfaction with asthma treatment is associated with bet-
ter adherence and achievement of treatment goals. While medication changes are 
sometimes instigated for clinical or financial reasons, changes without patients’ 
knowledge or involvement (‘non-consented switch’ [NCS]) can impact symptom 
control and patient-health care provider (HCP) relationships. This study explored 
experiences of patients who had a NCS and subsequently requested and received a 
second switch (SS). Methods: Interviews were conducted with 13 UK adult asthma 
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analysis was performed on real-world observational data from the years 2010-2013 
in The Netherlands. Data on use and adherence was collected, in patients who were 
dispensed bupropion or varenicline in community pharmacies for the first time. 
Adherence was defined a using minimal 80% of the in guidelines recommended 
duration and intensity of use. Results: The study cohort consisted of 4,412 users of 
pSCT. The number of prescriptions was stable at 0.5 prescriptions per 1,000 inhabit-
ants (dispensing prevalence, dp) during 2010. The prevalence was on average 0.8 
dp, with peaks in the the 1st and 4th quarters of 2011. In 2012, the prevalence was 
stable at 0.4 dp. In 2013 was on average 0.5 dp, with a small peak in the 1st quarter. 
Adherence was 18% in 2010 and 2012 (non-reimbursement period), and 21% in 2011 
and 2013 (reimbursement period). ConClusions: Not only the likelihood of start-
ing smoking cessation, but also the extent of adherence to pharmacologic smoking 
cessation is higher during reimbursement. Increasing the awareness of health care 
providers on adherence issues is warranted.
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objeCtives: Exacerbations are considered one of the main drivers of costs of 
Chronic Obstructive Pulmonary Disease (COPD). In moderate to severe COPD 
patients with a history of exacerbations, the addition of an inhaled corticosteroid 
(ICS) to a long acting β 2 agonist (LABA) has been associated with a decreased rate of 
exacerbations versus treatment with LABA alone. This study aims to estimate the 
health care costs that the addition of the ICS Fluticasone Furoate (FF) to the LABA 
vilanterol (VI) could avoid versus LABA monotherapy in Spanish patients due to 
the reduction of the rate of exacerbations. Methods: The number of moderate 
to severe COPD patients > 40 years old with a history of exacerbation potentially 
treated with FF+VI was estimated from Spanish prevalence data. 1-year Monte-Carlo 
simulations (one simulation per patient) were developed to simulate the number of 
moderate and severe exacerbations and the health care costs avoided with FF+VI 
versus VI from the National Health System (NHS) perspective. Monte-Carlo simula-
tion was chosen as it allows simulating the effect of changes in different param-
eters obtained from clinical studies to describe real-life distributions. Parameters 
used in the simulations were the yearly rate of moderate-severe exacerbations 
with FF+VI and VI obtained from pooled-analysis of two head-to-head clinical trials 
(NCT01009463 and NCT01017952) and the costs of moderate and severe exacerba-
tions obtained from an observational study in real-life Spanish setting. Results: 
18,098 patients were included. FF+VI could avoid 7,424 moderate and severe exac-
erbations (95% confidence interval 7,411; 7,438) vs VI. The reduction in the number 
of exacerbations could lead to average health care costs avoided to the NHS of 3,278, 
382€ (3,066, 703€ ; 3,336, 392€ ) in a year. ConClusions: Treatment with FF+VI could 
decrease the economic burden associated with COPD reducing the health care costs 
for the Spanish NHS due to the decreased rate of exacerbations compared with 
LABA (VI) monotherapy.
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objeCtives: Data of british specialists show, that 5-11 out of 1000 adults have com-
munity-acquired pneumonia (CAP) every year, which is 5-12% of all cases of lower 
respiratory tract infections. The rate of CAP took over 3% in the structure of total 
respiratory organs disease rate in Ukraine within years 2007-2011. Methods: The 
data of use of antimicrobial preparations (AP): cephalosporins (ceftriaxone), penicil-
lins (amoxicillin and enzyme inhibitor), macrolides (azithromycin) and fluoroqui-
nolones (ciprofloxacin, levofloxacin) for CAP treatment in Kharkiv hospital were 
used. Analysis of affordability as of index of payment capacity (Ca. s.) of trade names 
(TNs) provided in pharmaceutical market of Ukraine on indicated INN has been 
carried out to determine the availability of such preparations for wider population 
of Ukraine. Results: Results of the AP affordability analysis made in five groups of 
INN, showed, that the ratio of therapy of high, middle and low availability for each 
AP group is different, but in all pharmacological groups except for ceftriaxone group, 
highly available therapy prevails. Percentage of highly available preparations in the 
studied groups of INN is: azitromycin (92.2%) > ciprofloxacin (74.3%) > amoxicillin 
and enzyme inhibitor (67.5%) > ceftriaxone (49.02%) > levofloxacin (46.94 %). As of 
preparations of middle availability, costing 5% - 15% of average monthly salary, cef-
triaxone preparations are most (49.02%), azitromycin preparations are least (6.49%). 
There are no low availability preparations in ciprofloxacin fluoroquinolone group. 
Cephalosporins and macrolides group preparations have one AP of low availability. 
Pharmacotherapy with application of preparations-analogous to levofloxacin, is 
costly, as 32.7% of preparations of this group are preparations of low availability 
(16 AP). ConClusions: Antibacterial preparations needed for treatment of CAP 
are present in the pharmaceutical market of Ukraine in wide range of preparations 
and cost. It makes them available to various social groups.
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objeCtives: Though tobacco price increases are effective in reducing tobacco con-
sumption and prevalence of smoking, tobacco-tax in Japan is still lower than those in 
other developed countries. General public, particularly non-smokers, may think that 
inflammatory formulations were discontinued during 12 months after asthma diag-
nosis. ConClusions: Asthma treatment utilization patterns reflect poor asthma 
control among newly diagnosed elderly patients, and initiation of anti-inflammatory 
treatment after asthma diagnosis appears to be inconsistent with asthma manage-
ment guidelines.
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objeCtives: The primary objective of this study was to examine the accuracy of 
the GOLD 2011 strategy implementation among the Czech respiratory specialists, 
esp. with respect to the patients’ classification. The secondary objective was to 
explore what effect a misclassification has on inadequate use of inhaled corticos-
teroids (ICS). Methods: Multicentre cross-sectional study was conducted among 
COPD specialists, consisting of general questionnaire and patient-specific forms. A 
subjective classification into the GOLD 2011 groups as practiced by the health care 
professionals was examined and then compared with the objective classification 
achieved by rigorous software-computed classification. Adequacy of the ICS pre-
scription was evaluated with regard to the subjective classification. Results: GOLD 
2011 were claimed to be the leading guidelines for 143 out of 144 specialists involved, 
often accompanied by CPPS guidelines (83.3%) and the ACP/ACCP/ATS/ERS standards 
(50.7%). Based on 1355 patient forms, a discrepancy between the subjective and 
objective classification was found in 32.8% of cases. The most common reason for 
incorrect classification was erroneous symptoms assessment resulting in either 
under-estimation in 23.9% of cases and over-estimation in 8.9% of the examined 
patients’ records. Specialists seeing more than 120 patients per month were most 
likely to misclassify their condition, i. e. in 36.7% of all seen patients. In general, 
whilst examining the subjectively-driven ICS prescription, it was found that 19.5% 
of patients received ICS incorrectly, while in 12.2% of cases the ICS was erroneously 
omitted. Furthermore, with consideration to the objectively computed classifica-
tion, it was discovered that 15.4% received ICS unnecessarily, whereas in 15.8% of 
cases the ICS was not prescribed though, in fact, it would be adequate seeing the 
patient’s condition. Women failed in correct prescription more frequently than men, 
predominantly by overprescribing ICS. ConClusions: Despite high awareness of 
the GOLD 2011 guidelines, its implementation is insufficient. Czech specialists tend 
to either under-classify or overuse the ICS.
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objeCtives: Twitter, a popular social media outlet, has become a useful tool for 
the study of social behavior through user interactions called tweets. The location 
time, and message content of tweets provide invaluable social and demographic 
information for an applied comparison of social behaviors across the world. Our 
goal is to determine the density and sentiment surrounding tobacco and e-cigarette 
tweets and link prevalence of word choices to tobacco and e-cigarette use at various 
localities. Methods: All tweets with geo-spatial coordinates are salvaged from the 
twitter-feed, representing approximately 1% of the entire twitter-sphere. Pattern 
matching by tobacco and e-cigarette related keywords yield approximately 20,000 
affiliated tweets per month from North America. The emotionally charged words 
that contribute to the positivity of various subsets of regional tweets are quantita-
tively measured using hedonometrics. We examined the density of these behavioral 
tweet indicators by region and tested the relationship between tweeted smoking 
sentiments and time-space-type coordinates over a 4-month span. Results: For 
states with ≥ 600 tobacco related tweets (N= 30), we find a strong positive correla-
tion (Pearson’s r= 0.54, p< 0.01) between the relative tweet density per state and 
the average positivity of tobacco related tweets. However, state-to-state sentiment 
comparisons suggest the attitude toward tobacco use can vary. We also explore 
the relationship between the ratio of tobacco tweets per state-to-state smoking 
rate estimates. Our results illustrate significant variation in smoking sentiments 
by state and at varying regional scopes. ConClusions: It is anticipated that real-
time analysis of nicotine and tobacco products using tweets will allow for more 
targeted forms of health policy planning and intervention. Regional density of 
nicotine and tobacco use related tweets yield insight to the prevalence of tobacco 
usage per capita. Sentiment analysis across the twitter-sphere can help illuminate 
hazardous health behavioral trends, which may lead to better targeting of health 
behavior interventions.
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bACkgRound: The discussion on the reimbursement of Smoking Cessation 
Treatment (SCT) has known many stages in The Netherlands. From January 2011, 
SCTs were reimbursed, until January 2012 when the reimbursement of nicotine 
replacement therapies (NRTs) and pharmacotherapeutic SCT (pSCT) was discon-
tinued. As of 2013, NRTs and pSCTs were again reimbursed for a maximum of one 
attempt per calendar year, provided they are accompanied by behavioural coun-
selling. objeCtives: To assess the impact of changes in reimbursement policy 
of pSCT on use and adherence. Methods: A retrospective dispensing database 
